Department of Otolaryngology-Head and Neck Surgery, University of Michigan Health System, Ann Arbor, MI, USA.
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Curr Treat Options Oncol. 2021 Feb 8;22(3):21. doi: 10.1007/s11864-021-00821-8.
Human papilloma virus (HPV) related head and neck cancer is rising in prevalence, preferentially affecting young patients and imparting long term toxicities. Despite this, there are no screening tests or clinical biomarkers for treatment monitoring. HPV circulating tumor DNA (HPV ctDNA) represents a novel circulating biomarker which may provide real-time assessment of tumor response to therapy and recurrence. Early work suggests the promise of this assay as a predictive biomarker in numerous clinical settings, namely risk of recurrence after chemoradiation in locally advanced disease. Advancement of these findings to the clinic will require a collaborative effort in the field, including technical harmonization of assay testing characteristics, understanding of the normal kinetics in patients being treated with standard of care therapies, and appropriately designed phase III trials prior to implementation in the clinic. If successful, HPV ctDNA has the potential to revolutionize clinical trial treatment paradigms and transform patient care.
人乳头瘤病毒（HPV）相关的头颈部癌症的发病率正在上升，优先影响年轻患者，并带来长期的毒性。尽管如此，目前还没有用于治疗监测的筛查试验或临床生物标志物。HPV 循环肿瘤 DNA（HPV ctDNA）是一种新型的循环生物标志物，它可以实时评估肿瘤对治疗和复发的反应。早期的工作表明，该检测方法作为一种预测生物标志物在许多临床环境中具有广阔的应用前景，例如在局部晚期疾病中放化疗后复发的风险。要将这些发现推进到临床实践，需要在该领域开展协作，包括对检测特性进行技术协调，了解接受标准治疗的患者的正常动力学特征，并在临床应用之前设计适当的 III 期试验。如果成功，HPV ctDNA 有可能彻底改变临床试验的治疗模式，改变患者的治疗方式。
